



a





Supplementary Fig 1 Body weight of HT-29-inoculated humanized NRG mouse (a) Changes in the weight of mice during in vivo study (Control group, n=20; Drug-treated groups, n=18) Error bars indicate the standard error of the mean

Supplementary Figure 2


a




b




c




d




e



f




g




Supplementary Fig 2 Immune cell proportion of tumor infiltration lymphocytes (TILs) in the tumors of drug-treated mice
 (a)-(b) Proportion of human lymphocytes in TILs (c)-(e) Proportion of CD4+ and CD8+ cells in human lymphocytes among TILs
 (f)-(g) Proportion of regulatory T cells among CD4+ T cells Bini, Binimetinib; Enco, Encorafenib; Durv, Durvalumab

a



b



Supplementary Fig 3 Drug toxicity of combination treatment of immune checkpoint inhibitor and BRAF or MEK inhibitor
 (a) H&E staining results of livers harvested from xenograft mice after the completion of drug treatment Scale bar, 100 μ m. (b) AST and ALT levels in mouse blood after the completion of drug treatment (n=14) Error bars indicate the standard error of the mean *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 in Student's t-test Bini, Binimetinib; Enco, Encorafenib; Durv, Durvalumab